Fed. Circ. Pauses 'Orange Book' Delisting For Jazz Drug
By Kelly Lienhard · December 14, 2022, 7:05 PM EST
Jazz Pharmaceuticals will be allowed to list its patent for a narcolepsy drug in health regulators' roster of approved drugs, at least for the near future, after the Federal Circuit granted the company's...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login